Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service hysterectomy, hysteroscopy & ablation cases in California: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (238 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 59 | 6,387 | 48% |
| 2020 | 50 | 5,664 | 50% |
| 2021 | 60 | 5,912 | 52% |
| 2022 | 70 | 6,545 | 53% |
| 2023 | 64 | 6,575 | 55% |
| 2024 | 85 | 6,904 | 56% |
| 2025 from claims | – | 6,874 6,308–7,273 | 56% |
| 2026 forecast | – | 7,112 6,257–8,207 | 56% |
| 2027 forecast | – | 7,315 6,253–8,717 | 56% |
| 2028 forecast | – | 7,523 6,277–9,211 | 56% |
| 2029 forecast | – | 7,737 6,319–9,702 | 57% |
| 2030 forecast | – | 7,956 6,374–10,196 | 57% |
Laparoscopic/robotic hysterectomy, hysteroscopic resection, endometrial ablation. Professional codes (what the surgeon bills): CPT 58571, 58573, 58558, 58563, 58353, 58356, 58661, 58662.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 27% of the cases CMS names in California; 57 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 4% inpatient hospital, 71% hospital outpatient, 13% surgery center, 12% office.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Arizona | 21 | 1,973+0.3%/yr | +0.3%/yr | 2.9 | 22% | 2,360 in 2030+3%/yr |
| Washington | 21 | 1,715−1.7%/yr | −1.7%/yr | 2.4 | 4% | 2,300 in 2030+5%/yr |
| Colorado | 11 | 1,230+1.8%/yr | +1.8%/yr | 2.8 | 8% | 1,580 in 2030+4.2%/yr |
| Oregon | 10 | 1,031+0.7%/yr | +0.7%/yr | 2.7 | 14% | 1,100 in 2030+1.1%/yr |
| Nevada | 3 | 560−0.8%/yr | −0.8%/yr | 2.1 | 20% | 610 in 2030+1.5%/yr |
| Idaho | 5 | 440+2.5%/yr | +2.5%/yr | 2.4 | 9% | 690 in 2030+7.8%/yr |
| New Mexico | 5 | 427−0.8%/yr | −0.8%/yr | 2.0 | 16% | 400 in 2030−1.2%/yr |
| Montana | 7 | 426+5.8%/yr | +5.8%/yr | 2.4 | 8% | 720 in 2030+9.1%/yr |
| Utah | 2 | 384−2.1%/yr | −2.1%/yr | 1.9 | 11% | 380 in 2030−0.1%/yr |
| Alaska | 2 | 275+7.4%/yr | +7.4%/yr | 2.3 | 26% | 220 in 2030−3.5%/yr |
| Hawaii | 2 | 214+5.1%/yr | +5.1%/yr | 1.9 | 14% | 220 in 2030+0.1%/yr |
| Wyoming | 0 | 120+2.1%/yr | +2.1%/yr | 1.1 | 20% | 140 in 2030+2.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 202 | 14,148−8%/yr | −8%/yr | 4.20.8× | 48% | 14,100 in 2030−0.1%/yr |
| Kidney stone management | 210 | 10,020+0.3%/yr | +0.3%/yr | 3.00.7× | 17% | 11,600 in 2030+2.5%/yr |
| Incontinence, prolapse & sacral neuromodulation | 73 | 5,242+0.1%/yr | +0.1%/yr | 1.60.7× | 20% | 6,070 in 2030+2.5%/yr |
| Prostatectomy & nephrectomy | 71 | 3,581+0.9%/yr | +0.9%/yr | 1.21.0× | 0% | 4,490 in 2030+3.9%/yr |
Hysterectomy, hysteroscopy & ablation in every state, and its device makers · Every procedure market in California · Every state · Compare with Arizona
Acessa Health leads with 42% of company spending on these surgeons in 2025, −26 pts on 2024.
In 2025, 13 companies reported engagement with California’s surgeons worth $260K in consulting, speaking, meals and travel tied to these products, about $3,058 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.